Table 3.
Non-parametric correlations between individual changes in sleep parameters because of metyrapone in subgroup (n = 11), and metyrapone memory enhancement for the reactivated versus non-reactivated story [(reactivated – non-reactivated memory performance)metyrapone condition – (reactivated – non-reactivated memory performance)placebo condition], as well as cortisol decrease (because of metyrapone during sleep) and cortisol decrease because of metyrapone during sleep [(AUCi6:45–9:45am)metyrapone condition – (AUCi6:45–9:45am)placebo condition]
| Sleep changes because of metyrapone | Memory enhancement for the reactivated story because of metyrapone | Cortisol decreases because of metyrapone during sleep |
|---|---|---|
| TSTM-PL | 0.055 (p = 0.815) | –0.444 (p = 0.095) |
| SEM-PL | –0.055 (p = 0.815) | –0.611 (p = 0.022) |
| IntrawakeM-PL | 0.055 (p = 0.815) | 0.611 (p = 0.022) |
| N1M-PL | 0.418 (p = 0.073) | 0.056 (p = 0.835) |
| N2M-PL | –0.236 (p = 0.312) | 0.389 (p = 0.144) |
| N3M-PL | 0.236 (p = 0.312) | –0.389 (p = 0.144) |
| REMM-PL | –0.127 (p = 0.586) | 0.0 (p = 1) |
TST: total sleep time; SE: sleep efficiency; N1: NREM sleep stage 1; N2: NREM sleep stage 2; N3: NREM sleep stage 3; REM: rapid eye movement sleep stage. Statistically significant differences between conditions are depicted in bold.